Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly …
Sharemaestro market context Trend signal active 52 weeks +23.9% · Next-week setup positive 59.0%